GlassScriptPhysician profile
Anuradha Hooda
NPI 1659981983
$1,557.62
in general payments reported to CMS, 2019-2025
19 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.20 · 2021: $39.17 · 2022: $76.14 · 2023: $62.92 · 2024: $553 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.17 |
| Education | $171.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $197.18 | 2021-2025 | Jaypirca, Verzenio |
| Incyte Corporation | $191.19 | 2022-2025 | Jakafi |
| Daiichi Sankyo INC. | $163.96 | 2024-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $155.40 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Regeneron Healthcare Solutions, INC. | $129.16 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $126.55 | 2022-2025 | Alunbrig, Ninlaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.97 | 2020-2021 | |
| Tempus Ai, INC | $91.27 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $77.37 | 2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $64.87 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $46.11 | 2024-2025 | Qinlock, Romvimza |
| Janssen Biotech, INC. | $41.72 | 2023-2025 | Erleada |
| Servier Pharmaceuticals LLC | $41.24 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $38.88 | 2024-2025 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $26.88 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $23.86 | 2024 | Mektovi, Braftovi |
| Sobi, INC | $19.57 | 2024 | |
| Adc Therapeutics America, INC. | $13.86 | 2024 | |
| Pharmaand Gmbh | $8.58 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Hooda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.